Trump Drug Pricing Plan May Include Rebate Pass-Through Push – Novartis CEO
Industry exec Jimenez hopes President Trump’s reform proposals, expected in next three months, will include measures to ensure manufacturer rebates are passed through to patients and encourage outcomes-based reimbursement contracts with payers.
You may also be interested in...
Lilly CEO David Ricks reflects on the state of play on drug pricing issues on Capitol Hill and in the Administration and the challenges he sees ahead.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.